121 related articles for article (PubMed ID: 36155891)
1. Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
Blauvelt A; Shi N; Burge R; Atiya B; Zhu B; Somani N; Ridenour T; Lew CR; Zimmerman NM; Murage MJ
Pharmacoecon Open; 2022 Nov; 6(6):871-880. PubMed ID: 36155891
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
[TBL] [Abstract][Full Text] [Related]
6. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
Blauvelt A; Shi N; Murage M; Ridenour T; Lew C; Somani N; Zhu B; Zimmerman N; Kern S; Burge R
J Drugs Dermatol; 2022 Apr; 21(4):399-407. PubMed ID: 35389589
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study.
Murage MJ; Princic N; Park J; Malatestinic W; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
ACR Open Rheumatol; 2021 Dec; 3(12):879-887. PubMed ID: 34550647
[TBL] [Abstract][Full Text] [Related]
9. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
10. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
[TBL] [Abstract][Full Text] [Related]
11. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
[TBL] [Abstract][Full Text] [Related]
12. Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature.
AlMutairi N; Eassa BI
Postepy Dermatol Alergol; 2021 Apr; 38(2):281-288. PubMed ID: 36751540
[TBL] [Abstract][Full Text] [Related]
13. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
Zidane M; Dressler C; Gaskins M; Nast A
JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice.
Leonardi C; Tao R; Setayeshgar S; Wang S; Burge R; Zhu B; Malatestinic WN
J Dermatolog Treat; 2022 Jun; 33(4):2278-2284. PubMed ID: 34236934
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour TL; Lew CR; Zimmerman NM; Atiya B; Murage MJ
J Am Acad Dermatol; 2022 Mar; 86(3):581-589. PubMed ID: 34252464
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis.
Murage MJ; Gilligan AM; Tran O; Goldblum O; Burge R; Lin CY; Qureshi A
J Dermatolog Treat; 2021 Feb; 32(1):56-63. PubMed ID: 31696745
[No Abstract] [Full Text] [Related]
17. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.
Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
Patient Prefer Adherence; 2020; 14():517-527. PubMed ID: 32210539
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
19. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan.
Tada Y; Soliman AM; Ishii K; Sakuma R; Puig L; Davis M; Nunag D; Pinter A; Imafuku S
Dermatol Ther (Heidelb); 2024 Jan; 14(1):99-114. PubMed ID: 38019410
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]